BioMarin Deutschland
This company is committed to the communities it treats beyond the therapies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $1.0b | Post IPO Equity | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 14 % | 14 % | 9 % | (1 %) | 14 % | 15 % | 18 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (1 %) | - | 3 % | 8 % | 13 % | 22 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (5 %) | (1 %) | 46 % | (3 %) | 7 % | 7 % | 15 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 47 % | 42 % | 34 % | 34 % | 31 % | 31 % | 26 % |
Source: Company filings or news article
Related Content
BioMarin Pharmaceutical Inc. is a global biotechnology company that develops and commercializes therapies for people with rare and life-threatening genetic diseases. The company was founded in 1997 by Christopher Starr and Grant W. Denison Jr. and is headquartered in San Rafael, California.
BioMarin's business model is focused on the development and commercialization of orphan drugs, which are pharmaceuticals developed to treat rare medical conditions. The company's revenue is generated from the sale of its products, which include a portfolio of commercialized therapies and a pipeline of product candidates. BioMarin's target market includes patients with rare genetic diseases, and its customers are primarily specialty pharmacies and hospitals.
The company's product portfolio includes several approved therapies, such as Vimizim, Naglazyme, and Kuvan, which are used to treat various genetic disorders. BioMarin's development pipeline includes a number of product candidates in various stages of clinical development for the treatment of other rare diseases. The company's focus on rare diseases allows it to operate in a niche market with less competition than the broader pharmaceutical industry.
Keywords: biotechnology, rare diseases, orphan drugs, genetic disorders, pharmaceuticals, therapies, clinical development, biopharmaceutical, enzyme replacement therapy, metabolic disease
Tech stack
Investments by BioMarin Deutschland
Edit